As next-generation antibody formats, including bispecific antibodies, move rapidly toward the clinic, early-stage biotech teams face increasing uncertainty around where development risks may arise, how early decisions influence IND readiness, and how to progress quickly without creating downstream rework.
Drawing on experience from more than 70 bispecific development programs, this white paper explores how platform approaches, prior knowledge, high-throughput experimentation and targeted optimization can be combined to support more adaptive, knowledge-driven development of complex biologics.
Why read this white paper?
Discover how to:
- Identify development risks earlier and focus resources where molecule-specific challenges genuinely require attention.
- Determine when proven platform approaches can accelerate development and when targeted adaptation is needed.
- Navigate analytical, purification, and formulation challenges using prior knowledge, high-throughput approaches, and adaptable toolboxes.
- Reduce unnecessary development work and downstream rework by making more informed decisions earlier.
- Apply lessons from 70+ bispecific programs to build a more predictable path toward IND readiness and beyond.
